
WASHINGTON — President Trump will nominate Dr. Scott Gottlieb, a longtime drug industry financier and advocate for deregulation, to run the Food and Drug Administration, the White House said Friday.
Gottlieb, 44, is a physician and resident fellow at the conservative American Enterprise Institute. He trained at Mount Sinai School of Medicine, then pursued an unusual career that has taken him from hospitals to Wall Street to the FDA and back to Wall Street. A prolific writer and speaker on medical innovation, Gottlieb served as an FDA deputy commissioner under George W. Bush and has frequently testified before Congress.
His opposition to many regulations at an agency entrusted with protecting consumer safety could draw scrutiny from Democrats on the Senate’s Committee on Health, Education, Labor, and Pensions, which must approve nominations at the FDA. The nomination of the current FDA commissioner, Dr. Robert Califf, was stalled for months, with some lawmakers arguing that his close ties to the drug industry should have disqualified him from the job.

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.